Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors
Yıl: 2021 Cilt: 46 Sayı: 4 Sayfa Aralığı: 1401 - 1408 Metin Dili: İngilizce DOI: 10.17826/cumj.976041 İndeks Tarihi: 29-07-2022
Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors
Öz: Purpose: The aim of the present study was to evaluate survivin immunoexpression and the clinicopathologic correlations in serous borderline ovarian tumors (BOT) patients ≤ 40 years old. Materials and Methods: A total of 36 BOT cases were evaluated. After excluding the mucinous type and patients over 40 years of age, 20 serous BOT cases meeting the criteria were included. A similar number of benign ovarian cysts and 20 serous malign ovarian tumors were randomly included as the control group. The patients were then staged based on their surgical findings and 2014 FIGO criteria, and their histological tumor types obtained from pathological specimens were determined using WHO criteria. The survivin levels in the specimens were analyzed using immunohistochemical assays. Results: Positive survivin expression was detected in 10% of benign tumors, 100% of serous BOTs, and 100% of serous malign ovarian tumors. Mean survivin immunoreactivity was statistically similar between groups and it was found to be significantly higher in both groups compared to the control group. Survivin expression was positively correlated with FIGO stage, tumor grade, microinvasion, and micropapillary pattern. Conclusion: Survivin immunoexpression is correlated with the malignancy potential of serous BOTs, and that survivin immune expression may be a histopathological marker that will help in making a decision on fertilitysparing surgery and follow upin young patients.
Anahtar Kelime: Seröz borderline over tümörleri olan reprodüktif çağdaki hastalarda survivin immünoekspresyonunun klinikopatolojik önemi
Öz: Amaç: Bu çalışmanın amacı, 40 yaş ve altındaki seröz borderline over tümörü (BOT) olan hastalarda survivin immünoekspresyonunu ve klinikopatolojik korelasyonları değerlendirmektir. Gereç ve Yöntem: Toplam 36 BOT vakası değerlendirildi. Musinöz tip ve 40 yaş üzeri hastalar dışlandıktan sonra kriterleri karşılayan 20 seröz BOT vakası dahil edildi. 20 benign over kisti ile 20 seröz malign over tümörü kontrol grubu olarak rastgele dahil edildi. Hastalar daha sonra cerrahi bulguları ve 2014 FIGO kriterlerine göre evrelendirildi ve patolojik örneklerden elde edilen histolojik tümör tipleri WHO kriterlerine göre belirlendi. Örneklerdeki survivin seviyeleri, immünohistokimyasal testler kullanılarak analiz edildi. Bulgular: Pozitif survivin ekspresyonu, iyi huylu tümörlerin %10'unda, seröz BOT'ların %100'ünde ve seröz malign over tümörlerinin %100'ünde tespit edildi. Ortalama survivin immünreaktivitesi açısından gruplar arasında istatistiksel olarak fark yoktu, her iki grupta da kontrol grubuna göre anlamlı derecede yüksek olarak saptandı. Survivin ekspresyonu, seröz BOT grubunda FIGO evresi, tümör derecesi, mikroinvazyon ve mikropapiller patern ile pozitif korelasyon gösterdi. Sonuç: Survivin immün ekspresyonunun seröz BOT'ların malignite potansiyeli ile korele olduğunu ve survivin immün ekspresyonunun genç hastalarda fertilite koruyucu cerrahiye karar vermede ve takipte yardımcı olacak histopatolojik bir belirteç olabileceğini düşündürmektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125-42.
- 2. Trillsch F, Ruetzel JD, Herwig U, Doerste U, Woelber L, Grimm D et al. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (borderline ovarian tumor). J Ovarian Res. 2013;6:48.
- 3. Ureyen I, Karalok A, Tasci T, Turkmen O, Boran N, Tulunay G et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. Int J Gynecol Cancer. 2016;26:66-72.
- 4. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer. 2014;24:S5-8.
- 5. Helpman L, Beiner ME, Aviel-Ronen S, Perri T, Hogen L, Jakobson-Setton A et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril. 2015;104:138- 44.
- 6. Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res. 2007;27(4C):2803-8.
- 7. He X, Yang K, Wang H, Chen X, Wu H, Yao L et al. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis. PloS one. 2018;13:e0194463.
- 8. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2658-64.
- 9. Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N et al. Age-dependent differences in borderline ovarian tumours (borderline ovarian tumor) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROborderline ovarian tumor study. Ann Oncol. 2014;25:1320-7.
- 10. Turan G, Usta CS, Usta A, Kanter M, Tavli L, Karacan M et al. The expression of HER-2/neu (cerbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables. J Mol Hist. 2014;4:679-87.
- 11. Lin CK, Chao TK, Yu CP, Yu MH, Jin JS.. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 2009;117:162-75.
- 12. He X, Yang K, Wang H, Chen X, Wu H, Yao L et al. Expression and clinical significance of survivin in ovarian cancer: a meta-analysis. PloS One. 2018;13:e0194463.
- 13. Seong SJ, Kim DH, Kim MK, Song T.Controversies in borderline ovarian tumors. J Gynecol Oncol. 2015;26:343–9.
- 14. Cusido M, Balaguero L, Hernandez G, Falcón O, Rodríguez-Escudero FJ, Vargas JA et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104:617–22.
- 15. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2011;120:480–4.
- 16. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;400:1117-23.
- 17. Tamm, Y. Wang, E. Sausville E, Scudiero DA, Vigna N, Oltersdorf Tet al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Res. 1998;58:5315-20.
- 18. Plett H, Harter P, Ataseven B, Heitz F, Prader S, Schneider S et al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol. 2020;157:411-7.
- 19. Sozen H, Vatansever D, Topuz S, Iyibozkurt C, Kandemir H, Yalçin I et al. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution. J Obstet Gynecol. 2019;39:253-8.
- 20. Qian XQ, Hua XP, Wu JH, Shen YM, Cheng XD, Wan XY.. Clinical predictors of recurrence and prognostic value of lymph node involvement in the serous borderline ovarian tumor. Int J Gynecol Cancer. 2018;28:279-82.
- 21. Bendifallah S, Ballester M, Uzan C, Fauvet R, Morice P, Darai E.. Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors. Am J Obstet Gynecol. 2014;211:631-6.
| APA | ŞAHİN E, MADENDAĞ Y, KARAKAŞ E, akgun h, TOPALOĞLU N, KIRLANGIÇ M (2021). Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. , 1401 - 1408. 10.17826/cumj.976041 |
| Chicago | ŞAHİN Erdem,MADENDAĞ Yusuf,KARAKAŞ Erol,akgun hulya,TOPALOĞLU Nahit,KIRLANGIÇ Mehmet Mete Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. (2021): 1401 - 1408. 10.17826/cumj.976041 |
| MLA | ŞAHİN Erdem,MADENDAĞ Yusuf,KARAKAŞ Erol,akgun hulya,TOPALOĞLU Nahit,KIRLANGIÇ Mehmet Mete Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. , 2021, ss.1401 - 1408. 10.17826/cumj.976041 |
| AMA | ŞAHİN E,MADENDAĞ Y,KARAKAŞ E,akgun h,TOPALOĞLU N,KIRLANGIÇ M Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. . 2021; 1401 - 1408. 10.17826/cumj.976041 |
| Vancouver | ŞAHİN E,MADENDAĞ Y,KARAKAŞ E,akgun h,TOPALOĞLU N,KIRLANGIÇ M Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. . 2021; 1401 - 1408. 10.17826/cumj.976041 |
| IEEE | ŞAHİN E,MADENDAĞ Y,KARAKAŞ E,akgun h,TOPALOĞLU N,KIRLANGIÇ M "Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors." , ss.1401 - 1408, 2021. 10.17826/cumj.976041 |
| ISNAD | ŞAHİN, Erdem vd. "Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors". (2021), 1401-1408. https://doi.org/10.17826/cumj.976041 |
| APA | ŞAHİN E, MADENDAĞ Y, KARAKAŞ E, akgun h, TOPALOĞLU N, KIRLANGIÇ M (2021). Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. Cukurova Medical Journal, 46(4), 1401 - 1408. 10.17826/cumj.976041 |
| Chicago | ŞAHİN Erdem,MADENDAĞ Yusuf,KARAKAŞ Erol,akgun hulya,TOPALOĞLU Nahit,KIRLANGIÇ Mehmet Mete Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. Cukurova Medical Journal 46, no.4 (2021): 1401 - 1408. 10.17826/cumj.976041 |
| MLA | ŞAHİN Erdem,MADENDAĞ Yusuf,KARAKAŞ Erol,akgun hulya,TOPALOĞLU Nahit,KIRLANGIÇ Mehmet Mete Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. Cukurova Medical Journal, vol.46, no.4, 2021, ss.1401 - 1408. 10.17826/cumj.976041 |
| AMA | ŞAHİN E,MADENDAĞ Y,KARAKAŞ E,akgun h,TOPALOĞLU N,KIRLANGIÇ M Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. Cukurova Medical Journal. 2021; 46(4): 1401 - 1408. 10.17826/cumj.976041 |
| Vancouver | ŞAHİN E,MADENDAĞ Y,KARAKAŞ E,akgun h,TOPALOĞLU N,KIRLANGIÇ M Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors. Cukurova Medical Journal. 2021; 46(4): 1401 - 1408. 10.17826/cumj.976041 |
| IEEE | ŞAHİN E,MADENDAĞ Y,KARAKAŞ E,akgun h,TOPALOĞLU N,KIRLANGIÇ M "Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors." Cukurova Medical Journal, 46, ss.1401 - 1408, 2021. 10.17826/cumj.976041 |
| ISNAD | ŞAHİN, Erdem vd. "Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors". Cukurova Medical Journal 46/4 (2021), 1401-1408. https://doi.org/10.17826/cumj.976041 |
